HomeHome
TradeTrade
SpotFuturesStocks
LendLendBPBP
ToolsTools
WatchlistsScreenerGraphsCalendarRates
SupportSupport

More

​$​0123456789​.01234567890123456789​

Today

$0.00

+0.00%

Mkt Cap

Volume

Next Earnings

ChartFinancialsEarningsAbout
Relmada Therapeutics, Inc. Common Stock

Relmada Therapeutics, Inc. Common Stock

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

relmada.com

Ticker

RLMD

Market cap

$279.53M

IPO Date

Mar 3, 2014

Employees

17

All
Crypto
Stocks
Asset

Brokerage services in your region are provided through Trek Brokerage Services Limited, a company licensed by the Anjouan Offshore Finance Authority, acting as Intermediary Broker pursuant to the Backpack Securities Brokerage Services Terms of Service. Please see our Brokerage Services Terms and Conditions available here. Investing in stocks involves risks, including the total loss of your investment. The value of investments can go down as well as up, and past performance is not a reliable indicator of future results. You should consider seeking independent financial or legal advice before making any investment decision. It is your responsibility to ensure that your use of this platform and any investments made comply with the laws and regulations of your jurisdiction.